DMK Pharmaceuticals (NASDAQ:DMK) Shares Down 4.3%

Shares of DMK Pharmaceuticals Co. (NASDAQ:DMKGet Free Report) fell 4.3% during mid-day trading on Wednesday . The company traded as low as $0.47 and last traded at $0.49. 244,385 shares were traded during trading, a decline of 76% from the average session volume of 1,014,613 shares. The stock had previously closed at $0.51.

DMK Pharmaceuticals Price Performance

DMK Pharmaceuticals (NASDAQ:DMKGet Free Report) last released its quarterly earnings data on Monday, August 21st. The company reported ($2.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million during the quarter.

DMK Pharmaceuticals Company Profile

(Get Free Report)

DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder.

Further Reading

Receive News & Ratings for DMK Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DMK Pharmaceuticals and related companies with's FREE daily email newsletter.